Idera's IMO-8400 misses in Phase II for dermatomyositis

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) reported in June that IMO-8400 missed the primary

Read the full 124 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE